Target Audience: The target audience for Mayo Clinic Proceedings is primarily internal medicine physicians and other clinicians who wish to advance their current knowledge of clinical medicine and who wish to stay abreast of advances in medical research. Statement of Need: General internists and primary care physicians must maintain an extensive knowledge base on a wide variety of topics covering all body systems as well as common and uncommon disorders. Mayo Clinic Proceedings aims to leverage the expertise of its authors to help physicians understand best practices in diagnosis and management of conditions encountered in the clinical setting. Accreditation: Mayo Clinic College of Medicine and Science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Statement: Mayo Clinic College of Medicine and Science designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s).
TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Learning Objectives: On completion of this article, you should be able to (1) recognize that rheumatoid arthritis is a heterogeneous disease and the implications for the response to treatment; (2) distinguish between primary and secondary nonresponders to antietumor necrosis factor therapy and integrate this knowledge in treatment decisions for patients with rheumatoid arthritis who are inadequate responders to tumor necrosis factor inhibition; and (3) assess baseline characteristics of patients with rheumatoid arthritis that may be predictive of the response to biologic treatment and formulate the implications for a stratified medicine approach.
Disclosures: As a provider accredited by ACCME, Mayo Clinic College of Medicine and Science (Mayo School of Continuous Professional Development) must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course Director(s), Planning Committee members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so that those participants in the activity may formulate their own judgments regarding the presentation.
In their editorial and administrative roles, Karl A. Nath, MBChB, Terry L. Jopke, Kimberly D. Sankey, and Nicki M. Smith, MPA, have control of the content of this program but have no relevant financial relationship(s) with industry. Dr Wijbrandts served as an expert consultant to MSD. Dr Tak is an employee and shareholder of GlaxoSmithKline.
Method of Participation:
In order to claim credit, participants must complete the following: 1. Read the activity. 2. Complete the online CME Test and Evaluation. Participants must achieve a score of 80% on the CME Test. One retake is allowed. Visit www.mayoclinicproceedings.org, select CME, and then select CME articles to locate this article online to access the online process. On successful completion of the online test and evaluation, you can instantly download and print your certificate of credit. 1 It is important to note that patients with the same diagnosis can present with different signs and symptoms. Patients with rapid radiographic progression characterized by loss of cartilage and bone erosions will experience loss of function in early disease. Extra-articular manifestations such as pleuritis, pericarditis, and formation of rheumatoid nodules can be found in some patients. These extra-articular manifestations have become rare since the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs). There are different immunological and molecular mechanisms involved in different subsets of RA. For instance, patients can be either positive or negative for autoantibodies such as anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF). The presence of ACPA is associated with more rapid joint destruction 2, 3 and the presence of genotypes encoding the shared epitope, 4, 5 smoking, 4, 6 and periodontitis. 7 Heterogeneity has also been shown by studies of the major target of the disease, the synovium. Patients with RA with the same clinical symptoms may have different patterns of synovial cell infiltration, 8, 9 cytokine expression, 10, 11 activation of genes associated with inflammation, 12, 13 and gene expression in fibroblast-like synoviocytes. 14, 15 The notion that RA is a heterogeneous syndrome rather than a disease entity is also supported by the variability in clinical response to treatment. Biologic disease-modifying antirheumatic drugs that are used in daily clinical practice have diverse modes of action that either inhibit the effects of tumor necrosis factor (TNF; infliximab, adalimumab, etanercept, golimumab, and certolizumab), block the antiinterleukin 6 (IL-6) receptor (tocilizumab), deplete B cells (rituximab), or interfere with T-cell costimulatory signaling (abatacept). In addition to bDMARDs, there are targeted synthetic DMARDs. The first approved targeted synthetic DMARD is the Janus kinase inhibitor tofacitinib. A variable response to targeted treatment has been shown for TNF blocker, [16] [17] [18] [19] [20] rituximab, 21 abatacept, 22 tocilizumab, 23 and tofacitinib. 24 On the group level, comparable clinical responses have been observed among different mechanisms of action, but patients who respond to a specific bDMARD are not necessarily the same as those who respond to another. 25 It will be important to become better at predicting which patients are more likely to respond to a specific mechanism to improve the riskbenefit ratio and cost-effectiveness in individual patients as well as the overall treatment success on the population level ( Figure 1 ). 25 PREDICTORS OF RESPONSE TO ANTI-TNF TREATMENT Clinical improvement after TNF inhibition is observed in approximately 60% to 70% of patients who previously failed conventional synthetic DMARD (csDMARD) treatment such as methotrexate (MTX). This means that 30% to 40% of patients do not respond. At present, no factors have been identified that fully explain or predict response to anti-TNF therapy, but pretreatment differences at baseline between patient groups have been identified.
POTENTIAL SYNOVIAL AND PERIPHERAL BLOOD BIOMARKERS PREDICTIVE OF CLINICAL RESPONSE TO ANTI-TNF TREATMENT
A small study (n¼8) has suggested that pretreatment increased synovial synthesis of TNF might be related to clinical efficacy. 26 A study of 143 patients with active RA found increased synovial tissue TNF expression in patients who subsequently exhibited clinical improvement (change in disease activity score in 28 joints [DDAS28] !1.2 at week 16) after initiation of infliximab treatment compared with those who did not (DDAS28 <1.2 at week 16). 27 In addition, an increased number of synovial macrophages, including CD163 þ resident macrophages and myeloid-related protein 8 þ (MRP8) and MRP14 þ infiltrating macrophages, as well as an increased number of synovial T cells were found in responders compared with nonresponders. Both macrophages and T cells are the main TNFproducing cells in RA synovium. Although differences were observed between groups, no distinct threshold in synovial TNF expression levels could be found differentiating responders from nonresponders to anti-TNF therapy, which is consistent with the clinical experience that the response to anti-TNF therapy is not a dichotomous phenomenon. 28 This implies that response is determined by complex multifactorial biologic mechanisms. Multivariate logistic regression analysis of synovial markers revealed that the baseline synovial TNF expression in the synovial sublining explained approximately 10% of the variance in response to therapy. After adjusting for disease activity measured by DAS28 at baseline, this increased to 17%. 27 Hence, these studies confirm that biomarkers predictive of response to anti-TNF therapy might be identified. Although the predictive value of synovial TNF expression is statistically significant, the effect is overall limited, making it invaluable for personalized health care. In line with these findings, another study found that response to anti-TNF therapy is related to higher TNF bioactivity in peripheral blood. 29 A subsequent study revealed a highly significant relationship between the presence of synovial lymphocyte aggregates at baseline in the synovium and clinical response to infliximab treatment at 16 weeks (P¼.008). 30 When the presence of synovial lymphocyte aggregates at baseline was added to a combined prediction model with synovial TNF expression, DAS28 at baseline, and presence of ACPA, the explained variance in response increased from 19% to 29%. The positive predictive value (PPV) was 85%, and the negative predictive value (NPV) was 53%. 30 Other synovial tissue studies using gene array analysis have shown that patients with a pronounced inflammatory gene expression profile at baseline are more likely to exhibit a favorable response to anti-TNF therapy 31, 32 ; results have, however, been somewhat variable. The notion that synovial tissue analysis may help to predict clinical response on the group level in the context of stratified medicine is supported by a study describing 4 synovial subtypes using gene array analysis in 2 small cohorts of patients with RA of 49 and 20 patients, respectively. 34 The distinct gene expression signatures were classified as lymphoid, myeloid, low inflammation, and fibroid subtype. Based on our findings, it was hypothesized that patients with the myeloid phenotype, showing overrepresentation of myeloid and TNF-associated gene expression, would exhibit the best response to anti-TNF therapy. This was subsequently tested in an independent cohort of patients with RA. 32 Expression of the myeloid gene set at baseline was markedly higher in patients with a subsequent good EULAR response than in nonresponders. Based on the synovial subgroup phenotypes, an exploration was performed of possible representative serum biomarkers relating to predominant biological processes. The chosen biomarkers were soluble intercellular adhesion molecule (sICAM) and C-X-C motif chemokine 13 (CXCL13). Serum levels were determined at baseline in 198 serum samples of 326 patients with RA that received either tocilizumab or adalimumab monotherapy 35 and related to ACR clinical response at week 24. After looking at independent serum levels, a combination of 2 biomarkers was made by creating 4 groups with high/low, low/high, high/high, or low/low results. The patient subgroup that exhibited the combination sICAM high /CXCL13 low had the highest clinical response to adalimumab treatment. Conversely, patients who exhibited the combination sICAM low /CXCL13 high had the highest response to tocilizumab. 34 In accordance with the findings discussed above, no dichotomous phenomenon was found in this study, as the remaining patients in the high/high and low/low subgroups exhibited intermediate ACR50 response rates. 34 Future work is needed to validate these findings in independent patient groups.
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Another study that used transcription profiling of peripheral blood monocytes from patients with RA identified CD11c as a potential biomarker distinguishing at baseline between responders and nonresponders to adalimumab. CD11c is a transmembrane protein on various hematopoietic cells such as monocytes, macrophages, and neutrophils but less frequent on B cells. 36 CD11c levels were significantly correlated with ACR response, but they were not predictive of response to anti-TNF therapy in patients who concomitantly used MTX, hereby limiting its use as a predictive biomarker because anti-TNF therapy is usually combined with MTX.
A recent study describes the predictive role of serum MRP8/14 complex (calprotectin) levels in the peripheral blood of patients with RA. Myeloid-related protein 8 (S100A8) and MRP14 (S100A9) are endogenous Tolllike receptor 4 ligands that are expressed in granulocytes and monocytes 37 and promote inflammatory processes in vivo. 38 To explore the potentially predictive role as a biomarker of response in RA, serum MRP8/14 levels were measured in a prospective cohort of 170 patients treated with adalimumab (n¼86), infliximab (n¼60), or rituximab (n¼24) (see the Table for an overview of studies of potential predictors). One hundred twenty-three patients were classified as (good and moderate) responders, and 47 were nonresponders to treatment according to the EULAR response criteria. The levels of MRP8/14 were measured at baseline and weeks 4 and 16 after the initiation of treatment. Responders exhibited significantly higher MRP8/14 protein complex levels at baseline compared with nonresponders in each prospective cohort (P¼.010, P¼.001, and P<.001, respectively) ( Figure 2) . 39 In patients treated with adalimumab, the PPV for response of a high baseline serum MRP8/14 level (cutoff at a median level of 995 ng/mL) was 86%, and the NPV for nonresponse of a low baseline serum MRP8/14 level was 35%, with a sensitivity of 57% and a specificity of 71%. In patients treated with infliximab, the PPV of a high level of serum MRP8/14 (cutoff at a median level of 2027 ng/mL) was 93%, with an NPV of 43%, a sensitivity of 62%, and a specificity of 86%. In patients treated with rituximab, the PPV of high levels (cutoff at a median level of 1665 ng/mL) for predicting response was 92%, with an NPV of predicting nonresponse also being high at 83%, yielding a sensitivity of 85% and a specificity of 91%. 39 These data indicate that serum Tak et al, 53 2011
Chatzidionysiou et al, 47 2011
Sellam et al, 54 2011
Gardette et al, 55 2014
Isaacs et al, 56 2013
Sokolove et al, 57 2016
(high anti-CCP titer) Gottenberg et al, 49 2012
Gottenberg et al, 51 2016
Male sex Kleinert et al, 58 2012
Burmester et al, 59 2008
Hyrich et al, 60 2006
Younger age Burmester et al, 59 2008
Pers et al, 43 2014
Previous failure of TNF blocker Kleinert et al, 58 2012
TNF blocker naivety Burmester et al, 59 2008
Concomitant DMARD use Burmester et al, 59 2008
Current smoking Hyrich et al, 60 2006
Abhishek et al, 61 2010
Glintborg et al, 62 2016
Low IFN gene expression in PB Thurlings et al, 63 2010
Raterman et al, 64 MRP8/14 levels were consistently higher in responders to targeted treatment, independent of the specific mechanism of action. In responders to adalimumab and infliximab, at week 4 after the initiation of treatment, serum levels were decreased but they remained stable in nonresponders. Logistic regression analysis revealed that having high MRP8/14 serum levels at baseline increased the odds of being a responder by 3.3 up to 55.
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A treatment algorithm based on the measurement of MRP8/14 levels together with clinical predictors suggested that this may have predictive potential, although validation is needed in independent cohorts. 71 Another interesting potential biomarker is C-reactive protein (CRP) levels measured in peripheral blood. The change in the first 3 months of treatment is associated with longterm response. Data from 662 patients treated with infliximab in the open label observational REMARK study indicated that CRP levels decline rapidly within 2 weeks of treatment in all patients, but a rebound in CRP levels was observed at weeks 6 and 14 in nonresponders. 40 It was however not possible to predict response reliably on the basis of the change in CRP levels during the first 2 weeks. Another study found that the clinical response during the first 3 months of treatment predicts remission (disease activity score in 28 joints including C-reactive protein level [DAS28-CRP] <2.6) and low disease activity (DAS28-CRP <3.2) at 6 months after the initiation of treatment. 41 This was investigated in 866 patients with early RA who participated in the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab (OPTIMA) trial. They were treated with adalimumab with or without MTX. Disease activity score in 28 joints including C-reactive protein level, physician's global assessment of arthritis, and Health Assessment Questionnaire (HAQ) at week 12 were selected as predictors to calculate the prediction score per individual for clinical response at week 26. The NPV for DAS28-CRP less than 2.6 was 94.61%, and the PPV was 85.19%. 41 Several studies have investigated the relationship between the presence of RF and ACPA at baseline on the one hand and the response to anti-TNF treatment on the other, with conflicting results. [44] [45] [46] 52 Taken together, the effect of ACPA and RF status on clinical response to anti-TNF therapy is uncertain with contradictory results in different studies.
BASELINE PATIENT CHARACTERISTICS AS PREDICTORS OF CLINICAL RESPONSE TO ANTI-TNF TREATMENT
The previous sections described clinical (measures of disease activity) and molecular biomarkers at baseline as well as changes in these variables during the first few months as predictors of subsequent clinical response. There have also been studies of baseline patient characteristics in relationship to clinical response, including sex, age, body mass index (BMI; calculated as the weight in kilograms divided by the height in meters square), smoking, and vagus nerve tone. One study of 2625 patients treated with adalimumab found that improvement in DAS28 at 12 months was significantly greater in male patients than in female patients. The concomitant use of MTX was also a positive predictor of therapeutic response. 58 In the same study, previous bDMARD use was a negative predictor of response. Consistent with these findings, another open label trial in 6610 patients treated with adalimumab confirmed male sex and younger age as predictors of minimal disease activity and DAS28 remission (DAS28 <2.6) at week 12. Similarly, concomitant csDMARD use and anti-TNF therapy naivety were predictive of favorable response on the group level. 59 A positive effect of male sex on clinical response, but no effect of age, was also found in a British registry study of 2879 patients treated with etanercept and infliximab. 60 Two studies of patients with RA treated with infliximab found on average a better response in patients with lower BMI. 66, 67 Another study of patients treated with infliximab, adalimumab, or etanercept found that in the total study population only 15.2% of patients with BMI greater than 30 kg/m 2 achieved remission after 1 year vs 32% of patients with BMI less than 30 kg/m 2 . 68 After separate analysis of different TNF blockers, this difference was only statistically significant for infliximab users. 68 Current smoking has been shown to lower the response to anti-TNF therapy in patients with RA in 2 studies of 2879 and 395 patients, respectively. 60, 61 A comparable negative effect of current smoking status on clinical efficacy of anti-TNF therapy was found in a study of 1576 patients with ankylosing spondylitis, 62 in which multivariate analyses revealed that current smokers had a lower odds of achieving BASDAI 50%/20-mm response (treatment response by [50% or 20 mm reduction in Bath AS Disease Activity Index]) at 6 months than did never smokers, independent of TNF inhibitor type. 62 The effect of the autonomic nervous system on drug response is a research field worth further exploration. A small study of 25 patients with RA and 8 with psoriatic arthritis found that increased parasympathetic tonus determined through measurement of resting heart rate and heart rate variability predicted subsequent ACR response after treatment. Poor response was associated with low parasympathetic measures. 72 
PREDICTORS OF RESPONSE TO RITUXIMAB TREATMENT
A study evaluating changes in synovial cell populations 4 and 16 weeks after the initiation of rituximab treatment in 24 patients with RA found no baseline synovial characteristics predicting response at week 24. 73 Sixteen weeks after rituximab treatment, the number of synovial B cells, T cells, and macrophages were decreased. The change in synovial B cells after treatment was not significantly different between response groups. However, with linear regression analysis, the decrease in plasma cells at weeks 4 and 16 was shown to be predictive of the decrease in DAS28 at week 24 and correlated with a reduction in serum ACPA levels. The extent of decrease in plasma cells differed between responders and nonresponders. 73 Other studies have supported the concept that the clinical effect of rituximab treatment in RA is in part explained by changes in plasma cells (derived from CD20 þ B cells) and leads to a subsequent reduction of autoantibody levels. [73] [74] [75] In a study of patients with RA who failed at least 1 TNF blocker, RF positivity and normal levels of CD19 þ B cells together with increased
(memory) peripheral blood B cells predicted a better response to rituximab treatment, in particular when all parameters were present. 76 Several studies have shown that patients with RA who are RF and/or ACPA positive are more likely to respond to rituximab treatment than are seronegative patients. 47, [53] [54] [55] This was confirmed in a meta-analysis of 2177 patients (of which 761 were treated with placebo). 56 Another potential biomarker of response is the presence of a type I interferon (IFN) signature at baseline. Specifically, high IFN response gene expression levels were found in peripheral blood mononuclear cells of nonresponders compared with low baseline expression levels in good responders. 63, 64 The concomitant use of prednisolone may interfere with IFN gene expression, thereby influencing the predictive value of the type I IFN response as a predictor of the response to rituximab treatment. The predictive value of the type I IFN score was better in patients who did not use prednisolone at baseline, with an area under the receiver operating characteristic curve of 0.975, a sensitivity of 88%, and a specificity of 100%. 65 Type 1 IFNs may stimulate the production of a proliferationinduced ligand (APRIL) and B-lymphocyte stimulator (BLyS) and directly enhance B cell survival.
As described above, baseline serum MRP8/14 levels were found to be higher in responders than in nonresponders to rituximab treatment. At week 16 after the initiation of treatment, serum levels decreased by 59% in responders, but not in nonresponders. 39 Data are still limited and need confirmation in a larger independent cohort.
With regard to baseline patient characteristics, 1 study explored the relationship between BMI and response to rituximab treatment and found no predictive effect. 67 
PREDICTORS OF RESPONSE TO TOCILIZUMAB TREATMENT
There are limited data on predictors of the response to tocilizumab. A small study of 40 patients with RA described a significant difference in type I IFN response gene expression (IFI6, MX2, and OASL; for expansion of gene symbols, see www.genenames.org) in peripheral blood between nonresponders and responders. Receiver operating characteristic analysis of models incorporating these genes revealed that the maximum area under the curve was 0.947 in predicting a moderate or good response to tocilizumab in the small validation cohort (n¼15). 77 Other relatively small studies suggested baseline serum IL-6 receptor levels as a predictor of clinical remission at week 24 78 and serum levels of IL-1b and D-dimer at 4 weeks after treatment as predictors of response at week 52. 79 High baseline natural killer cell numbers were also associated with remission after 3 months of tocilizumab therapy. 80 All these studies need to be confirmed in independent cohorts.
In a relatively large study of 530 patients with RA, low HAQ score, high DAS28, and absence of concomitant prednisolone use at baseline were predictive of a good and moderate EULAR response to tocilizumab. In multivariate analyses, predictors of discontinuation of treatment were low baseline levels of CRP, high HAQ score, and previous exposure to different biologic agents. 81 In a multicenter observational study of 126 patients with RA who failed previous bDMARD therapy, the predictors of achieving DAS28-erythrocyte sedimentation rate (ESR) remission at 3 months were baseline ESR greater than 30 mm/h, CRP level greater than 10 mg/L, and the presence of extra-articular disease manifestations. In contrast, a lower likelihood of achieving DAS28 remission was associated with higher baseline hemoglobin concentrations, higher baseline DAS28-ESR, and the number of previous DMARDs and biological therapies used. 42 Several studies reported no relationship between RF or ACPA positivity and the clinical response to tocilizumab treatment. 42, 43, 82 In contrast, a relatively small study of 58 patients suggested an association between high IgM-RF titers and clinical disease activity index remission at week 24. 48 One study of 204 patients with RA found that younger age is a predictor of a good and moderate EULAR response at week 24. 43 There is no evidence for an effect of BMI on response to tocilizumab treatment in RA. 69, 70 One study of 204 patients with RA could not find an effect of current smoking on EULAR response after 24 weeks of tocilizumab treatment. 43 PREDICTORS OF RESPONSE TO ABATACEPT TREATMENT There are only a few studies exploring biomarkers predictive of response to abatacept. A study of 71 patients using multivariate logistic regression suggested that a lower proportion of terminally differentiated effect or memory cells among total CD8
þ T lymphocytes at baseline are predictive of treatment discontinuation (28 patients discontinued treatment because of lack of efficacy and 7 because of adverse events). 83 Receiver operating characteristic analysis revealed a statistically significant performance of this biomarker for prediction of therapy discontinuation (area under the curve, 0.760AE0.07; P¼.002). Another study evaluated peripheral blood CD28 À T-cell subsets at baseline in 32 patients. Patients with low baseline numbers of CD8 þ CD28 À T cells had a more than 4-fold higher probability of achieving remission within 6 months compared with patients with higher levels of this subset of T cells. 84 Although these studies are of interest, the findings need to be confirmed in independent patient populations.
A study of 318 patients revealed that patients with the highest IgG-ACPA levels (measured using the antiecyclic citrullinated peptide test) at baseline found significantly greater clinical improvement in DAS28-CRP after abatacept treatment (but not after adalimumab treatment) than did patients with lower ACPA levels, although ACPA-negative patients could still respond to abatacept. 57 Consistent with these findings, a cohort study of 733 patients found that after correction for disease activity, the proportion of antiecyclic citrullinated peptide-positive patients was higher in responders than in nonresponders, which was not found for RF-positive status at baseline. 49 Other studies confirmed that there is no relationship between RF at baseline and subsequent response to abatacept treatment. 50, 51 The predictive value of ACPA status has, however, not been confirmed in all studies. A recent article describing pooled data from 9 international registries (2942 patients) reported no relationship between ACPA status at baseline and EULAR response rates after 1 year. 51 Taken together, it is unlikely that autoantibody status can be used as a predictor of response to abatacept treatment.
PREDICTORS OF RESPONSE TO TOFACITINIB TREATMENT
A small randomized controlled trial of tofacitinib treatment in 29 patients with RA with inadequate response to MTX found a statistically significant correlation between changes in synovial phosphorylation of signal transducer and activator of transcription 3 and clinical response after 4 months of treatment. 85 These data need further confirmation.
GENETICS AND GENOMICS IN PREDICTION OF RESPONSE TO BIOLOGICAL TREATMENT OF RA
We refer to a recent comprehensive review on genomic research discussing studies of genes associated with response to biologic therapy in RA. 86 Using genome-wide association studies, several gene loci have been identified that are related to the response to anti-TNF therapy. 86, 87 A recent study of 1239 participants found that patients with the IFNGrs2069705C allele had a significantly better response to TNF blocking therapy than did those carrying the wild-type allele. 88 As another example, various transforming growth factor b1 single nucleotide polymorphisms SNPs were associated with a good response to rituximab treatment. 89 Two studies have suggested a potential role for BAFF gene 871C>T promoter polymorphism and the 158 V/F polymorphism of FcGR3A in prediction of response to rituximab treatment. 90, 91 Data from genomic studies have, however, been inconclusive: different studies have reported different associations, and it has often been difficult to reproduce identified gene loci in independent cohorts. 92 This could in part be explained by variability in study populations based on, for instance, ethnicity and concomitant or previous drug use as well as by differences in methodology. Furthermore, the effect of genotype on clinical response to targeted treatment in complex disorders may be limited.
ROLE OF ANTIDRUG ANTIBODIES
It is important to distinguish between primary nonresponse and secondary nonresponse, as the underlying mechanisms may be completely different. Primary nonresponse can be defined as a lack of clinical improvement within the first 12 to 16 weeks of treatment. 25 Secondary nonresponse can be defined as a decrease or loss of response after initial improvement after the initiation of treatment, which can be explained by the formation of antidrug antibodies 93 or counterregulatory mechanisms driving inflammation. Antidrug antibodies were detected in 43% of patients with RA within the first year of infliximab treatment (86% of patients used concomitant MTX). Patients with antidrug antibodies were less often classified as responders. 94 Antidrug antibodies are not only formed against chimeric antibodies such as infliximab. In patients treated with the humanized monoclonal TNF blocker adalimumab, 17% of patients formed antidrug antibodies within 28 weeks of the initiation of treatment, of whom 79% used concomitant MTX. 95 Nonresponders were significantly more often antidrug antibody positive than were good responders. 95 After follow-up of 3 years, the presence of antidrug antibodies was associated with lower drug levels and a lower likelihood of remission or low disease activity. 93 Although antidrug antibody formation may explain secondary nonresponse unrelated to the mechanism of disease in an individual patient, primary nonresponse to TNF inhibition may be explained by relatively less TNFdependent disease. Clinical response to a second TNF blocker is diminished on the group level as compared with response to a first TNF blocker, which can be explained by the subgroup of patients with less TNFdependent disease that failed the first TNF inhibitor and subsequently also the second one. [96] [97] [98] [99] However, clinical response to a second TNF blocker is not decreased in patients who exhibited secondary nonresponse due to antidrug antibody formation. 98, 100 Patients who failed adalimumab or infliximab treatment associated with detectable antidrug antibodies had a similar response after switching to etanercept as compared with patients who were TNF blocker naïve. However, patients who failed adalimumab or infliximab without detectable antidrug antibodies had a diminished response to a second TNF blocker. 100 The same was found for infliximab users with or without antidrug antibodies who switched to adalimumab. 98 These data are consistent with other studies, indicating that the clinical response to a second or third TNF blocker is generally diminished in nonresponders to a first TNF blocker. 101, 102 Taken together, primary nonresponse to anti-TNF therapy may be due to a mechanism other than TNF bioactivity driving the underlying inflammatory process, reducing the likelihood of response to a second TNF blocker. Secondary nonresponse may in part be explained by antidrug antibody formation. 25 Thus, measurement of antidrug antibodies may help to predict which patient may benefit from switching to a second TNF blocker vs a different mechanism of action as part of a personalized medicine strategy.
PERSONALIZED TREATMENT ALGORITHM FOR THE USE OF BIOLOGIC AGENTS
In patients with RA who have failed 1 or a combination of csDMARDs together with low-dose glucocorticoids, biologic treatment may be indicated. According to the EULAR recommendations from 2013, first choice biologic agents in patients who have failed csDMARDs are TNF blockers, abatacept, and tocilizumab. 103 TNF blockers are often prescribed as first bDMARDs because these drugs have been on the market for a long time. Later studies have shown early and sustained remission with abatacept and tocilizumab as well when used as first bDMARDs. 104, 105 If there is lack of clinical response to a TNF blocker, one could choose a second TNF blocker (in the case of secondary nonresponse), abatacept, tocilizumab, rituximab, or tofacitinib (in the United States). The decision as to which biologic agent to select may be influenced by patient factors such as the risk of chronic infections (such as tuberculosis) and the possibility to use concomitant MTX. For instance, tocilizumab is the only bDMARD that was shown to be equally effective when used as monotherapy 25 * Abatacept and tocilizumab can also be selected as first biologic disease-modifying antirheumatic drug. Rituximab initial non-responders switch to different mechanism of action. ** JAK inhibitor recommended for use after failure of biologic disease-modifying antirheumatic drugs. 103 ACPA ¼ anti-citrullinated protein antibody; csDMARD ¼ conventional synthetic disease-modifying antirheumatic drug; JAK ¼ janus kinase; RA ¼ rheumatoid arthritis; RF ¼ rheumatoid factor; TNF ¼ tumor necrosis factor. compared with combination therapy with MTX. 105 At present, no biomarkers are known that can predict response to any biologic DMARD in an individual patient with a high level of certainty. However, clinical response may be enriched on the group level in the context of stratified medicine. When switching to a second bDMARD after failing a first TNF blocker, it is relevant to distinguish between primary and secondary nonresponders, as discussed above (Figure 3) . Primary nonresponders are less likely to respond to a second TNF blocker, as they have less TNFdependent disease. If after an initial response to TNF blocking therapy the disease flares again because of antidrug antibody formation, one could try a second TNF inhibitor or a different mechanism of action. As discussed above, autoantibody-positive patients are more likely to respond to rituximab treatment than are autoantibody-negative patients. Thus, it would make more sense to treat an autoantibodynegative patient with tocilizumab or abatacept than with rituximab if a patient has failed treatment with a TNF inhibitor and a decision has been made to treat with a different mechanism of action ( Figure 3 ). It can be anticipated that combinations of clinical and new molecular biomarkers will be used in the future to improve the prediction of response to treatment and move from stratified medicine on the group level to precision medicine in individual patients. Clearly, it would be best to identify biomarkers that can be used at baseline before the patient has received treatment. However, a second best and still valuable approach would be to predict the likelihood of remission after prolonged treatment on the basis of the initial response during the first few weeks of treatment. This would allow more rapid cycling of treatments until the patient gets the therapy with the best chance of success of achieving disease remission and protection against progressive joint destruction.
CONCLUSION
Several studies have been performed to identify predictors of response to biologic therapy, but the clinical relevance is still limited to personalized therapy in daily practice (see the Table for overview). Various potential biomarkers still need confirmation in independent studies. Large randomized controlled switch studies are underway that may help to further improve recommendations for personalized treatment. There are, however, already biomarkers that help distinguish between responders and nonresponders on the group level. This has formed the basis for a preliminary treatment algorithm that may assist treatment decisions for patients who failed a first TNF blocker (Figure 3 ). This algorithm needs to evolve over time, when new data become available. 71 The development of better personalized treatment algorithms will be important to further improve the riskbenefit ratio as well as cost-effectiveness of biologic treatments.
Abbreviations and Acronyms: ACPA = anti-citrullinated protein antibody; ACR = American College of Rheumatology; bDMARD = biologic disease-modifying antirheumatic drug; BMI = body mass index; CRP = C-reactive protein; csDMARD = conventional synthetic disease-modifying antirheumatic drug; CXCL13 = C-X-C motif chemokine 13; DAS28 = disease activity score in 28 joints DAS28-CRP = disease activity score in 28 joints including Creactive protein level; ESR = erythrocyte sedimentation rate; EULAR = European League Against Rheumatism; HAQ = Health Assessment Questionnaire; IFN = interferon; IL = interleukin; MRP8 and MRP14 = myeloid-related proteins 8 and 14; MTX = methotrexate; NPV = negative predictive value; PPV = positive predictive value; RA = rheumatoid arthritis; RF = rheumatoid factor; sICAM = soluble intercellular adhesion molecule; TNF = tumor necrosis factor Potential Competing Interests: Dr Wijbrandts served as an expert consultant to MSD. Dr Tak is an employee and shareholder of GlaxoSmithKline.
